[Study on the in vitro and in vivo thrombolytic efficacy of bispecific antifibrin-antiurokinase monoclonal antibodies].
To evaluate the thrombolytic efficacy of bispecfic antifibrin-antiurokinase monoclonal antibodies. Murine hybrid hybridomas secreting bispecific monoclonal antibodies (bsMcAbs) were prepared by fusing a mutant hybridomas secreting antifibrin McAbs with spleen cells of murine immunized with urokinase. The binding power of bsMcAbs with fibrin or urokinase was determined by ELISA method. The in vitro thrombolytic efficacy was measured by the dissolving rate of 131I-plasma clot. The in vivo thrombolytic efficacy was measured by using the rabbit jugular vein thrombus model. 8 strains of bsMcAbs have been obtained. ELISA experiments showed that bsMcAbs have very strong binding power with fibrin or urokinase. The bsMcAbs bound with urokinase increased the in vitro thrombolytic efficacy of urokinase by 15.5%. The in vivo thrombolytic efficacy of bsMcAbs bound with urokinase was 1.6-2.1 times as high as urokinase. Monoclonal antibody-directed thrombolytic agents have advantages of high specificity and strong local thrombolytic efficacy. It is well worth going on further study.